Novel Imaging diagnostics and treatment modalities for clear cell kidney cancer
|Coordinator||AKURU PHARMA AB|
|Funding from Vinnova||SEK 500 000|
|Project duration||July 2017 - August 2018|
Purpose and goal
The purpose of this project was to develop a new specific diagnostic method for detecting clear cell kidney cancer based on an already existing method of detecting the biomarker DAT. We therefore initiated a clinical trial for the evaluation of the existing diagnostic drug. In this trial we have analyzed five patients with suspected metastatic renal cancer and have thereafter assessed the diagnostic method.
Expected results and effects
The results from the trial showed that the existing method was not adequate to be used for detection of kidney tumors as it is today. We believe that DAT detection can be used to identify clear cell kidney cancer tumors, but increased sensitivity and specificity compared to the current method is required. New molecules for DAT detection have been identified and the business plan has thus been updated and improved. In the project process, Key Opinion Leaders have been identified and valuable contacts have been established
Planned approach and implementation
Akuru Pharma has worked as a coordinating party in this project and has coordinated interaction between the monitor, clinic and creator of CRF. The trial has been conducted in collaboration with Lund University and Region Skåne. Region Skåne has been responsible for the patient recruitment and the scan. Analysis of the results has been performed by independent radiologist. The coordinator has executed all communication with relevant authorities such as the MPA, ethical vetting board and radiation protection authorities.